Metabolic & Cardiometabolic
statins decreases major adverse cardiovascular events (secondary prevention)
In plain terms: Do statins reduce major cardiovascular events in patients with established cardiovascular disease?
Strong support Metabolic & Cardiometabolic
Part of: 💊 statins
RefutedContestedStrong support
consensus score 1.00
Yes — among the best-supported claims in cardiology: large RCTs and CTT meta-analyses show a consistent ~20-25% relative risk reduction in major vascular events per ~1 mmol/L LDL lowering.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
3 support 0 contradict 0 tested null 0 mixed · 3 sources, 3 independent groups · 4 superseded — pooled inside a review, counted once
The evidence (11)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Kritharides, Nicholls 2015 · Future Cardiol | meta-analysis | supports | high | COMMENTARY, no new data (PubMed PublicationType 'Comment'; CommentOn Lancet 2015;385:1397-405). The article's own opening line is 'Evaluation of: Fulcher et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 385(9976), 1397-1405 (2015).' It restates that result - 'statins reduced the risk of major vascular events by 21% for each mmol/l reduction of LDL cholesterol (relative risk: 0.79; 95% CI: 0.77-0.81)' - and concludes 'This study adds to existing literature in confirming that statins have demonstrable benefit in men and women.' Direction is correct; the vote is not independent. Zero-weighted per CONVENTIONS 5. The primary, Fulcher 2015 (PMID 25579834), is not yet in the vault. |
| Baigent, Blackwell, Emberson, Holland, Reith, Bhala, Peto, Barnes, Keech, Simes, Collins 2010 · Lancet 376(9753):1670-1681 | meta-analysis | supports | high | IPD meta-analysis, 26 RCTs / 170,000 participants, prespecified protocol, ITT. The statin-vs-control pool alone (21 trials, 129,526) tests statin against no statin: first major vascular events in 7136 (2.8%/yr) of 64,744 on statin vs 8934 (3.6%/yr) of 64,782 on control - a 22% reduction (95% CI 19-24, p<0.0001) for a 1.07 mmol/L LDL difference. All 26 trials combined: 22% per 1.0 mmol/L (95% CI 20-24). All-cause mortality 10% lower per mmol/L (RR 0.90, 0.87-0.93); no excess non-vascular mortality or cancer. |
| Federici M, Buzzetti R, Candido R, De Cosmo S, Pirillo A, Russo G, Sesti G, Avogaro A 2026 · Cardiovasc Diabetol 2026;25(1):156 | observational | supports | low | Narrative expert-opinion review (Cardiovasc Diabetol 2026;25(1):156; PMC subject type 'Review'; 'No datasets were generated or analysed during the current study'). It affirms the claim in its own words but on borrowed data: 'Reducing LDL-C by 1 mmol/L with statin therapy lowers overall mortality by 9% and cardiovascular mortality by 13% in patients with diabetes', and 'recent individual participant data meta-analyses from the Cholesterol Treatment Trialists' (CTT) Collaboration confirm that these effects are limited in magnitude and are outweighed by the substantial reduction in major cardiovascular events'; concluding 'statins remain the first-line lipid-lowering therapy for people with diabetes'. Both figures are transcribed from CTT, which this claim already holds as two sign-bearing appraisals (s16214597, s21067804, group ctt), so counting this again double-counts by construction: evidence_role: review, zero weight. The paper's own subject is bempedoic acid, not statins; its statin passage is background. Population is people with diabetes across mixed primary and secondary prevention, and the headline number is mortality rather than MACE, so it is directionally right but less precise than the claim. Funding: 'No specific funding was received for this work'; six of eight authors declare honoraria (four naming Daiichi Sankyo and/or Amgen; the article states no marketing rights — CAL #16 arithmetic fix). Full text read from PMC XML. |
| Mariani A 2025 · Appl Health Econ Health Policy | observational | supports | low | Cohort Markov cost-effectiveness model, not a statin trial: 'A cohort Markov model with a yearly cycle length was developed in Microsoft Excel to compare the costs and quality-adjusted life years (QALYs) for various cholesterol treatment escalation thresholds'. Every modelled person is already on a statin and the comparison is between escalation thresholds; the statin effect enters only as a borrowed parameter - 'The CTT collaboration has conducted various meta-analyses of statin trials; it has shown that lowering LDL-C by 1 mmol/L is associated with a proportional reduction in the rate of major CVD events of 22%'. Result reported is a threshold, not an event reduction: 'The most cost-effective threshold for lipid therapy escalation was found to be 2.2 mmol/L'. |
| LIPID Study Group 1998 · N Engl J Med | RCT | supports | high | LIPID: pravastatin in 9,014 CHD patients lowered coronary death 24% and total mortality 22% across a broad range of baseline cholesterol. ↩ SUPERSEDED — pooled in the review above, counted once |
| Burger, Dorresteijn, Koudstaal, Holtrop, Kastelein, Jukema, Ridker, Mosterd, Visseren 2024 · Atherosclerosis | meta-analysis | supports | high | Meta-analysis of 60 RCTs (408,959 participants, 51,425 major vascular events) of LDL-C lowering therapy: 'The HR for major vascular events per 1 mmol/L LDL-C reduction was 0.78 (95 % confidence interval [CI] 0.75-0.81)', and 'Consistent results were found for statin trials only, and all trials combined.' Correcting the prior extract: the benefit did NOT grow over treatment time — 'Follow-up duration was not associated with a change in the HR for major vascular events (HR for change per year 0.994; 95 % CI 0.970-1.020; p = 0.66).' Primary analyses pool statins with ezetimibe and PCSK9 inhibitors; the statin-only point estimate is not reported in the available abstract. |
| Cholesterol Treatment Trialists 2005 · Lancet | meta-analysis | supports | high | Meta-analysis of 90,056 patients in 14 trials: ~21% reduction in major vascular events per 1 mmol/L LDL reduction; benefit largely independent of baseline lipids. |
| Scandinavian Simvastatin Survival Study 1994 · Lancet | RCT | supports | high | 4S: simvastatin in 4,444 CHD patients cut all-cause mortality 30% (RR 0.70) and major coronary events 34% over 5.4 years — landmark secondary-prevention trial. ↩ SUPERSEDED — pooled in the review above, counted once |
| Kostapanos, Elisaf 2011 · World J Cardiol | RCT | supports | low | Narrative review of JUPITER and its published sub-analyses, contributing no original data: 'In this paper the most important secondary analyses of the JUPITER trial are discussed.' It restates the trial result — 'In JUPITER, rosuvastatin was associated with significant reductions in cardiovascular outcomes as well as in overall mortality compared with placebo' — with no effect sizes, no systematic search and no methods section, so it is a low-quality echo of a trial the vault already holds, not an independent test. |
| Heart Protection Study Collaborative Group 2002 · Lancet 2002 Jul 6;360(9326):7-22 | RCT | supports | high | HPS: simvastatin in 20,536 high-risk individuals cut major vascular events ~24% regardless of baseline LDL, age, sex, or diabetes status. ↩ SUPERSEDED — pooled in the review above, counted once |
| Cannon, Braunwald, McCabe, Rader, Rouleau, Belder, Joyal, Hill, Pfeffer, Skene 2004 · N Engl J Med. 2004 Apr 8;350(15):1495-504 | RCT | supports | high | PROVE IT-TIMI 22, n=4162 within 10 days of an acute coronary syndrome, mean 24 months: 'compared 40 mg of pravastatin daily (standard therapy) with 80 mg of atorvastatin daily (intensive therapy)' - BOTH arms received a statin; there was no placebo or untreated arm. Achieved median LDL 95 vs 62 mg/dL (P<0.001); primary composite at two years 26.3% vs 22.4%, 'a 16 percent reduction in the hazard ratio in favor of atorvastatin (P=0.005; 95 percent confidence interval, 5 to 26 percent)', the trial having been 'designed to establish the noninferiority of pravastatin as compared with atorvastatin' and having failed that test. So this is a within-class dose-intensity result: it ranks statin regimens and cannot speak to statin versus no statin, which the paper instead assumes up front - 'Lipid-lowering therapy with statins reduces the risk of cardiovascular events, but the optimal level of low-density lipoprotein (LDL) cholesterol is unclear.' Off-scope for this claim; on-scope for a statin dose-intensity claim the vault does not yet hold. ↩ SUPERSEDED — pooled in the review above, counted once |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.